查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1864205

食道癌市场按最终用户、癌症类型、疾病分期和治疗方法划分－2025年至2032年全球预测

Esophageal Cancer Market by End User, Cancer Type, Disease Stage, Treatment Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，食道癌市场规模将达到 310.1 亿美元，复合年增长率为 8.55%。

关键市场统计数据
基准年 2024 160.8亿美元
预计年份：2025年 174.5亿美元
预测年份 2032 310.1亿美元
复合年增长率 (%) 8.55%

本书简明扼要地介绍了当代食道癌治疗的临床复杂性、诊断创新以及医疗服务压力。

食道癌在各种医疗机构中持续构成复杂的临床和操作挑战。近年来，诊断技术的进步、对分子分型更深入的理解以及全身性治疗的快速发展都重塑了临床诊疗路径。同时，内视镜技术的改进和微创手术的发展也改变了根治性治疗和安宁疗护之间的平衡，因此需要多学科协作和更新的诊疗通讯协定。

临床医生和政策制定者面临着相互衝突的优先事项，包括将精准诊断融入常规实践、改进早期检测以加快疾病进展至可治癒阶段，以及确保新型系统性疗法能够公平地惠及合适的患者群体。这些挑战的背景是支付方动态、供应链压力以及监管机构对真实世界证据的重视。因此，相关人员必须将临床创新与务实的交付模式结合，并将治疗进展与人群层面疗效的改善联繫起来。

分子诊断、免疫肿瘤学以及不断变化的监管要求的进步如何共同改变食道癌的临床实践和医疗服务？

由于科学、技术和监管三大力量的融合，食道癌的治疗格局正在改变性变化。分子谱分析和次世代定序正在重新定义诊断流程，使临床医生能够在基因组层级区分腺癌和鳞状细胞癌，并识别HER2和EGFR突变等治疗标靶。这些进展正在加速标靶治疗治疗和联合治疗的应用，同时，基于生物标记分层，免疫疗法也不断拓展其适应症。

同时に、内视镜画像技术の向上や循环肿疡DNA検査の段阶的な检验など、诊断手法の改善により、早期発见と疾患モニタリングの実现可能性が高まっています。外科的治疗も进化しており、低侵袭食道切除术や回復促进通讯协定の导入により手术全期併发症が减少しています。规制経路は迅速核准や个别适応拡大に対応するよう适応しており、これに伴い临床医、支払者、製造业者はエビデンス创出と核准后データ収集の再考を迫られています。これらの変化は総合的に、个别化医疗の新たな机会を创出する一方で、アクセス、偿还、縦断的アウトカム测定に関する复雑さも生み出しています。

评估2025年关税调整对肿瘤供应链、采购惯例以及诊断和治疗取得途径​​的营运和策略影响。

2025年实施的关税调整和贸易政策变化对肿瘤治疗和诊断设备的供应链产生了实际的影响。部分进口商品关税的增加增加了某些医疗设备和特殊试剂的采购成本，迫使医院和诊所重新评估其供应商合约和库存策略。在某些情况下，这些压力加速了供应商多元化进程，并促使企业更加关注区域製造伙伴关係，以降低跨境关税波动带来的风险。

药品供应链正努力透过优化分销网络和策略采购来降低关税对高成本药物单位成本的影响。支付者和医疗系统正加强对采购选择的审查，以确保患者能够获得所需药物，同时控制新增营运成本。同时，製造商也在重新审视定价和合约签订方式，探索基于价值的合约模式，并在条件允许的情况下进行本地包装和组件采购。总而言之，这些调整凸显了适应性采购政策和弹性供应链规划的重要性，以确保接受复杂癌症治疗的患者能够获得持续的医疗服务。

整合式細項分析将临床中心、肿瘤组织学、疾病分期和多层治疗方法联繫起来，提供见解，从而指导个人化的临床和商业策略。

セグメンテーション分析により、医疗提供场所、肿疡生物学、病期分布、治疗方法における微妙な差异が明らかとなり、これらは临床経路やサービス设计に直接影响を及ぼします。外来手术センター、病院、専门クリニックなどのエンドユーザーを考虑する场合、处置件数、手术全期能力、および多分野にわたる调整の要件は、患者の处理能力やリソースの配分に影响を与える点で异なります。外来施设は効率性と短期滞在の管理を重视し、病院は包括的な手术全期および复雑な症例管理を提供し、専门クリニックは多くの场合、専门分野を细分化した外来治疗とフォローアップに重点を置いています。

以癌症类型检验腺癌和鳞状细胞癌之间的差异，可以发现它们在病因、危险因子和治疗敏感性方面有显着差异。腺癌常与胃食道逆流和巴瑞特氏食道症相关，且更适合基于分子标记的标靶治疗；而鳞状细胞癌则更常见于具有特定暴露风险的人群，并且对放射线治疗的反应可能不同。疾病分期分为I期、II期、III期和IV期，显示早期疾病应优先考虑根治性治疗方法，例如手术和内视镜切除，而晚期疾病则越来越需要全身治疗和综合姑息治疗策略，以维持患者的生活品质。

治疗分层涵盖化疗、免疫疗法、放射线治疗、手术和标靶治疗，其中化疗分为辅助性治疗、新辅助治疗和安宁化疗，这会影响治疗时机和顺序的选择。免疫疗法包括癌症疫苗和查核点抑制剂，每种疗法都有其特定的生物标记依赖性和毒性管理的考量。标靶治疗主要针对EGFR、HER2和VEGF抑制剂，其临床应用需要检验的生物标记检测和多学科治疗方案製定。这种多层次的分类凸显了协调诊断能力、临床专业知识和医保报销机制的重要性，以优化不同患者群体的治疗效果。

美洲、欧洲、中东/非洲和亚太地区区域系统动态对食道癌诊疗机会、诊断能力和治疗方法采纳的影响

区域动态影响临床实践模式、监管时间表和医疗服务取得途径，进而显着影响诊断和治疗方法的普及。儘管美洲地区聚集了众多卓越医疗中心，但各区域的资源可及性差异巨大，导致一些都市区能够获得最先进治疗，而偏远地区则更注重高效的医疗服务模式和分散的后续随访。虽然该地区的政策和报销体系通常有助于快速推广具有显着临床效益的治疗方法，但医疗服务取得方面的差距仍然是一项严峻的挑战。

欧洲、中东和非洲地区医疗保健系统的多样性体现在诊断能力和一次性支付方式的差异上，一些地区优先考虑集中式基因组检测，而另一些地区则依赖可操作的临床演算法。欧洲各市场的监管协调促进了临床试验的跨境合作，但患者能否获得治疗仍取决于当地的报销政策。在欧洲、中东和非洲部分地区，医疗资源限制和公共卫生优先事项正在影响旨在加强早期检测和建立标准化治疗路径的专案工作。

亚太地区正经历主导创新与全球治疗标准策略性应用并存的局面。多个市场中高运转率的临床中心能够促进临床试验的患者快速入组，并加速真实世界证据的生成；与此同时，该地区其他国家正在扩建分子诊断基础设施并发展相关人才队伍，以应对不断增长的发病率。在整个亚太地区，临床指引、诊断途径和价值证据的协调一致对于改善治疗效果、确保新兴治疗方法惠及目标患者群体仍然至关重要。

製药创新者、诊断开发商和医疗设备製造商之间竞争与合作的动态，正在塑造食道癌的治疗和诊断生态系统。

食道癌领域的竞争格局涵盖了成熟的製药公司、新兴的生物技术公司、诊断平台提供者以及专业医疗设备製造商。製药公司正致力于研发结合标靶治疗和免疫疗法的联合治疗，并主导生物标记进行适应症优化，以识别最有可能获益的患者群体。诊断公司则投资于能够可靠检测组织和液态生物检体检体中HER2、EGFR和其他可治疗突变的检测方法。同时，医疗设备製造商则专注于扩充性视镜和外科手术技术，以降低併发症率并支持门诊治疗模式。

治疗药物研发公司与诊断公司之间的合作日益重要，这有助于支持伴随诊断、高效招募临床试验参与者以及促进上市后证据的收集。规模较小的生物技术公司通常致力于探索创新的作用机製或新型抗原靶点，而大型公司可能会收购或授权这些技术以拓展其产品线。医疗系统和专科诊所也正从单纯的购买者转变为合作者，参与可操作的临床试验和註册研究，从而确定药物的真实疗效并为支付方的决策提供依据。临床创新、诊断检验和商业策略之间的相互作用将决定该领域的竞争格局，并最终决定哪些解决方案能够获得永续的临床应用。

为临床、商业和供应链领导者提供切实可行的策略，以加速食道癌治疗的公平获取并优化治疗价值

行业领导者应优先投资以弥补诊断能力差距，并支持以生物标记主导的治疗路径。加强与病理网络的合作，并投资于可扩展的分子检测基础设施，将缩短治疗启动时间，并改善标靶治疗和免疫疗法方案的患者选择。製造商和支付方还应在风险分担和基本契约模式方面展开合作，将报销与已证实的疗效挂钩，从而使更多患者能够获得高成本疗法，同时奖励真实世界证据的收集。

运営面では、ヘルスケア提供者は外科、肿疡内科、放射线肿疡学、支持疗法チーム间の多职种连携を强化し、治疗顺序の最适化と毒性管理を図るべきです。贸易政策の変动に伴う混乱を最小限に抑えるため、筹资策略の多様化と紧急时应对计画によるサプライチェーンの耐性を向上させる必要があります。最后に、患者支援団体や公众卫生机関との利害相关人员连携により、早期発见倡议や启発宣传活动を推进し、発症段阶における格差を解消することで、より多くの患者が根治性的治疗の恩恵を受けられるようにすべきです。

采用严谨的混合研究途径，结合专家咨询、临床证据综合和营运情境分析，为策略决策提供支援。

本研究基于多学科证据基础，整合了同行评审的临床文献、监管公告、临床指南更新以及对临床医生、诊断专家和供应链专业人员的访谈。主要研究包括一项结构化的专家咨询，旨在探讨治疗顺序、诊断效用和采购趋势；次要研究则整合了已发表的临床试验结果、监管措施和技术评估，为新兴趋势提供背景资讯。

此分析方法着重于将定性研究结果与已记录的临床证据和政策趋势进行交叉检验。它采用了调查方法，并运用情境分析来评估供应链和监管变化对营运的影响。报告重点阐述了共识领域，并指出了需要进行专案研究和前瞻性真实世界研究以加强决策的证据缺口。

简洁扼要的结论强调了整合诊断技术、治疗创新和系统层面韧性对于改善食道癌治疗效果的重要性。

摘要，食道癌的治疗正处于一个转折点，诊断的精准性、治疗的创新以及系统层面的适应能力将决定临床进展能否大规模转化为患者预后的改善。分子谱分析以及标靶治疗治疗和免疫疗法的拓展为个体化治疗提供了契机，但要充分发挥这些潜力，需要对诊断基础设施、多学科诊疗协调以及供应链韧性进行投资。

政策制定者、医疗服务提供者和行业相关人员必须携手合作，协调奖励，消除医疗资源获取方面的差距，并产生强有力的真实世界证据，以证明治疗的价值。透过聚焦可扩展的诊断技术、切实可行的治疗路径和合作协议，相关人员可以迅速将科学进步转化为食道癌患者切实的临床效益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 早期食道癌患者越来越多地采用微创内视镜消融疗法，可改善患者预后。
  • 将人工智慧演算法整合到内视镜检查中，以提高食道病变的早期检出率
  • 针对PD-1和PD-L1路径开发免疫疗法治疗难治性食道癌
  • 扩大液态生物检体技术在监测循环肿瘤DNA方面的应用，以指南个人化治疗策略
  • 透过製药公司和学术机构之间的策略合作，建构新型食道癌治疗药物研发管线
  • 新兴的以患者为中心的护理模式，结合远端医疗和穿戴式监测技术，为食道癌术后倖存者提供服务
  • 提高包含化疗和查核点抑制剂的新型联合治疗的报销核准

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 食道癌市场（以最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第九章 食道癌市场（依癌症类型划分）

  • 腺癌
  • 鳞状细胞癌

第十章 食道癌市场依疾病分期划分

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第十一章 食道癌治疗方法市场

  • 化疗
    • 辅助性治疗
    • 新辅助辅助性治疗
    • 安宁疗护
  • 免疫疗法
    • 癌症疫苗
    • 查核点抑制剂
  • 放射线治疗
  • 外科手术
  • 标靶治疗
    • EGFR抑制剂
    • HER2抑制剂
    • VEGF抑制剂

第十二章 食道癌市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 食道癌市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国食道癌市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Roche Holding AG
    • Johnson & Johnson
    • AstraZeneca PLC
    • Pfizer Inc.
    • Novartis AG
    • Amgen Inc.
    • AbbVie Inc.
    • Sanofi SA
Product Code: MRR-757B1C9CB069

The Esophageal Cancer Market is projected to grow by USD 31.01 billion at a CAGR of 8.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 16.08 billion
Estimated Year [2025] USD 17.45 billion
Forecast Year [2032] USD 31.01 billion
CAGR (%) 8.55%

A succinct introduction to the clinical complexities, diagnostic breakthroughs, and care delivery pressures defining contemporary esophageal cancer practice

Esophageal cancer continues to present complex clinical and operational challenges across diverse healthcare settings. Advances in diagnostics, a deeper understanding of molecular subtypes, and the rapid evolution of systemic therapies have all reshaped clinical pathways in recent years. Simultaneously, improvements in endoscopic techniques and minimally invasive surgery have altered the balance between curative intent and palliative care, requiring multidisciplinary coordination and updated care protocols.

Clinicians and policy makers face competing priorities: integrating precision diagnostics into routine workflows, improving early detection to shift stage distribution toward curable disease, and ensuring that novel systemic agents reach appropriate patient populations in an equitable manner. These imperatives are set against a backdrop of shifting payer dynamics, supply chain pressures, and regulatory emphasis on real-world evidence. Consequently, stakeholders must align clinical innovation with pragmatic delivery models to translate therapeutic progress into improved population-level outcomes.

How molecular diagnostics, immuno-oncology advances, and evolving regulatory expectations are jointly transforming clinical practice and care delivery in esophageal cancer

The landscape of esophageal cancer is undergoing transformative shifts driven by converging scientific, technological, and regulatory forces. Molecular profiling and next-generation sequencing are redefining diagnostic workflows, enabling clinicians to distinguish between adenocarcinoma and squamous cell carcinoma at a genomic level and to identify actionable targets such as HER2 and EGFR alterations. These advances have accelerated the adoption of targeted therapies and combination regimens, while immunotherapy continues to expand indications based on biomarker stratification.

Concurrently, improvements in diagnostic modalities, including enhanced endoscopic imaging and the incremental validation of circulating tumor DNA assays, are increasing the feasibility of earlier detection and disease monitoring. Surgical practice is evolving too, with minimally invasive esophagectomy and enhanced recovery protocols reducing perioperative morbidity. Regulatory pathways have adapted to accommodate accelerated approvals and bespoke label expansions, which, in turn, prompt clinicians, payers, and manufacturers to rethink evidence generation and post-approval data collection. Taken together, these shifts are creating new opportunities for personalized care but also introducing complexity around access, reimbursement, and longitudinal outcome measurement.

Assessing the operational and strategic consequences of 2025 tariff changes on oncology supply chains, procurement practices, and access to diagnostics and therapeutics

Tariff adjustments and trade policy changes implemented in 2025 have had a tangible impact on the supply chains that support oncology therapeutics and diagnostic devices. Increased duties on selected imports have raised procurement costs for some medical devices and specialty reagents, prompting hospitals and clinics to reassess vendor contracts and inventory strategies. These pressures have, in some cases, accelerated the diversification of supplier bases and stimulated interest in regional manufacturing partnerships to mitigate exposure to cross-border tariff volatility.

Pharmaceutical supply chains have responded by optimizing distribution networks and by engaging in strategic sourcing to lessen the per-unit impact of tariffs on high-cost therapies. Payers and health systems have increased scrutiny of procurement choices, seeking to preserve access while containing incremental operational expenses. In parallel, manufacturers have revisited pricing and contracting approaches, exploring value-based agreements and localized packaging or component sourcing where feasible. Collectively, these adjustments underscore the importance of adaptive procurement policies and resilient supply chain planning to ensure continuity of care for patients receiving complex cancer therapies.

Integrative segmentation insights linking care settings, tumor histology, disease stage, and layered treatment modalities to inform tailored clinical and commercial strategies

Segmentation analysis reveals nuanced differences across care delivery locations, tumor biology, stage distribution, and treatment modalities that directly influence clinical pathways and service design. When considering end users such as Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, procedural volumes, perioperative capabilities, and multidisciplinary coordination requirements differ in ways that affect patient throughput and resource allocation; ambulatory settings emphasize efficiency and short-stay management, hospitals provide comprehensive perioperative and complex case management, and specialty clinics often concentrate subspecialized outpatient therapies and follow-up.

Examining cancer type distinctions between Adenocarcinoma and Squamous Cell Carcinoma highlights divergent etiologies, risk factor profiles, and therapeutic vulnerabilities; adenocarcinoma is frequently associated with gastroesophageal reflux and Barrett's esophagus and often presents opportunities for targeted therapy based on molecular markers, whereas squamous disease may be more prevalent in populations with distinct exposure risks and can respond differently to chemoradiation approaches. Disease stage segmentation across Stage I, Stage II, Stage III, and Stage IV illustrates how early-stage management prioritizes curative-intent modalities including surgical and endoscopic resection, while advanced stages rely increasingly on systemic therapies and integrated palliative strategies to preserve quality of life.

Treatment type stratification spans Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy, with chemotherapy further subdivided into adjuvant, neoadjuvant, and palliative approaches that shape timing and sequencing decisions. Immunotherapeutic approaches include cancer vaccines and checkpoint inhibitors, each with specific biomarker dependencies and toxicity management considerations. Targeted therapies focus on EGFR inhibitors, HER2 inhibitors, and VEGF inhibitors, and their clinical integration depends on validated biomarker testing and multidisciplinary care planning. These layered segmentations underscore the importance of aligning diagnostic capabilities, clinical expertise, and reimbursement frameworks to optimize outcomes across distinct patient cohorts.

How regional system dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific influence access, diagnostic capacity, and therapeutic adoption in esophageal cancer

Regional dynamics shape clinical practice patterns, regulatory timelines, and access pathways in ways that meaningfully affect the adoption of diagnostics and therapeutics. In the Americas, concentrated centers of excellence coexist with broad regional variation in resource availability, producing a landscape where cutting-edge treatments are accessible in some urban hubs while peripheral systems emphasize efficient care delivery models and decentralized follow-up. Policy and reimbursement mechanisms in this region often drive rapid uptake of therapies with strong clinical benefit, but disparities in access remain a central concern.

In Europe, Middle East & Africa, heterogeneity across healthcare systems manifests in varying diagnostic capacity and bundled payment approaches, with some jurisdictions prioritizing centralized genomic testing and others relying on pragmatic clinical algorithms. Regulatory alignment across European markets facilitates cross-border collaboration on clinical trials but local reimbursement decisions continue to govern patient access. Capacity constraints and public health priorities in parts of the Middle East and Africa influence programmatic efforts to strengthen early detection and enable more standardized treatment pathways.

Asia-Pacific presents a mix of domestically driven innovation and strategic adoption of global therapeutic standards. High-volume clinical centers in several markets drive rapid accrual to trials and can accelerate real-world evidence generation, while other countries in the region expand infrastructure for molecular diagnostics and workforce training to address growing incidence. Across all regions, aligning clinical guidelines, diagnostic access, and value demonstration remains essential to improving outcomes and ensuring that emerging therapies reach appropriate patient groups.

Competitive and collaborative dynamics among pharmaceutical innovators, diagnostic developers, and device makers shaping therapeutic and diagnostic ecosystems in esophageal cancer

The competitive environment in esophageal cancer spans established pharmaceutical firms, emerging biotech companies, diagnostic platform providers, and specialized device manufacturers. Pharmaceutical developers are concentrating on combination regimens that pair targeted agents with immunotherapies and on refining biomarker-driven indications to identify patients most likely to benefit. Diagnostic companies are investing in assays that enable reliable detection of HER2, EGFR, and other actionable alterations from tissue and liquid biopsy specimens, while device manufacturers focus on scalable endoscopic and surgical technologies that reduce complication rates and support ambulatory care models.

Partnerships between therapeutic and diagnostic players are increasingly important to support companion diagnostics, enable streamlined trial enrollment, and facilitate post-market evidence collection. Smaller biotechnology firms often pursue innovative mechanisms of action and novel antigen targets, which larger firms may acquire or license to expand pipeline breadth. Health systems and specialty clinics are also evolving from purchasers into collaborators, participating in pragmatic trials and registries that help define real-world effectiveness and inform payer decisions. The interplay between clinical innovation, diagnostic validation, and commercial strategy defines the competitive contours of the field and will determine which solutions achieve sustainable clinical uptake.

Practical strategic recommendations for clinical, commercial, and supply chain leaders to accelerate equitable access and optimize therapeutic value in esophageal cancer

Industry leaders should prioritize investments that bridge diagnostic capability gaps and support biomarker-driven care pathways. Strengthening partnerships with pathology networks and investing in scalable molecular testing infrastructure will reduce time-to-treatment and improve patient selection for targeted and immunotherapeutic regimens. Manufacturers and payers should also collaborate on risk-sharing and value-based contracting models that align reimbursement with demonstrated outcomes, enabling broader access to high-cost therapies while incentivizing meaningful real-world evidence collection.

Operationally, healthcare providers should enhance multidisciplinary coordination across surgical, medical oncology, radiation oncology, and supportive care teams to optimize sequencing and manage toxicity. Supply chain resilience must be improved through diversified sourcing strategies and contingency planning to minimize disruptions related to trade policy volatility. Finally, stakeholder engagement with patient advocacy organizations and public health agencies can advance early detection initiatives and education campaigns, addressing disparities in presentation and enabling more patients to benefit from curative-intent interventions.

A rigorous mixed-methods research approach combining expert consultation, clinical evidence synthesis, and operational scenario analysis to inform strategic decision-making

This research integrates a multi-disciplinary evidence base combining peer-reviewed clinical literature, regulatory announcements, clinical guideline updates, and interviews with clinicians, diagnostics experts, and supply chain professionals. Primary research included structured expert consultations that explored therapeutic sequencing, diagnostic utility, and procurement dynamics, while secondary analysis synthesized published clinical trial outcomes, regulatory actions, and technology assessments to provide context for emerging trends.

Analytical approaches emphasized cross-validation of qualitative insights with documented clinical evidence and policy developments. The methodology prioritized transparency in data sources and assumptions, and applied scenario analysis to assess the operational implications of supply chain and regulatory shifts. Where applicable, the report highlights areas of consensus and identifies evidence gaps that warrant focused investigation or prospective real-world studies to strengthen decision-making.

A concise conclusion highlighting the imperative to integrate diagnostics, therapeutic innovation, and system-level resilience to improve outcomes in esophageal cancer

In summary, esophageal cancer management is at an inflection point in which diagnostic precision, therapeutic innovation, and system-level adaptability will determine whether clinical advances translate into improved patient outcomes at scale. Molecular profiling and the expansion of targeted and immune-based therapies offer tangible opportunities to personalize care, but realizing that potential requires investments in diagnostic infrastructure, multidisciplinary care coordination, and supply chain resilience.

Policymakers, providers, and industry stakeholders must work in concert to align incentives, address disparities in access, and commit to robust real-world evidence generation that substantiates therapeutic value. By focusing on scalable diagnostics, pragmatic treatment pathways, and collaborative contracting, stakeholders can accelerate the translation of scientific progress into meaningful clinical benefit for people living with esophageal cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of minimally invasive endoscopic ablation procedures for early-stage esophageal cancer improved patient outcomes
  • 5.2. Integration of artificial intelligence algorithms in endoscopic screening to enhance early detection of esophageal lesions
  • 5.3. Development of targeted immunotherapies addressing PD-1 and PD-L1 pathways for refractory esophageal carcinoma cases
  • 5.4. Expansion of liquid biopsy techniques for monitoring circulating tumor DNA to guide personalized treatment strategies
  • 5.5. Strategic partnerships between pharmaceutical companies and academic centers for novel esophageal cancer drug pipelines
  • 5.6. Emergence of patient-centric care models combining telemedicine and wearable monitoring for post-surgery esophageal cancer survivors
  • 5.7. Growth in reimbursement approvals for novel combination regimens incorporating chemotherapy and checkpoint inhibitors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Esophageal Cancer Market, by End User

  • 8.1. Ambulatory Surgical Centers
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Esophageal Cancer Market, by Cancer Type

  • 9.1. Adenocarcinoma
  • 9.2. Squamous Cell Carcinoma

10. Esophageal Cancer Market, by Disease Stage

  • 10.1. Stage I
  • 10.2. Stage Ii
  • 10.3. Stage Iii
  • 10.4. Stage Iv

11. Esophageal Cancer Market, by Treatment Type

  • 11.1. Chemotherapy
    • 11.1.1. Adjuvant Therapy
    • 11.1.2. Neoadjuvant Therapy
    • 11.1.3. Palliative Therapy
  • 11.2. Immunotherapy
    • 11.2.1. Cancer Vaccines
    • 11.2.2. Checkpoint Inhibitors
  • 11.3. Radiotherapy
  • 11.4. Surgery
  • 11.5. Targeted Therapy
    • 11.5.1. Egfr Inhibitors
    • 11.5.2. Her2 Inhibitors
    • 11.5.3. Vegf Inhibitors

12. Esophageal Cancer Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Esophageal Cancer Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Esophageal Cancer Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Merck & Co., Inc.
    • 15.3.2. Bristol-Myers Squibb Company
    • 15.3.3. Roche Holding AG
    • 15.3.4. Johnson & Johnson
    • 15.3.5. AstraZeneca PLC
    • 15.3.6. Pfizer Inc.
    • 15.3.7. Novartis AG
    • 15.3.8. Amgen Inc.
    • 15.3.9. AbbVie Inc.
    • 15.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. GCC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GCC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GCC ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GCC ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. GCC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 306. GCC ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 307. GCC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. GCC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. GCC ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. GCC ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 311. GCC ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. GCC ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. GCC ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 331. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS ESO